Skip to Main Content
Back to News

Lobbying Update: $60,000 of DANAHER CORPORATION lobbying was just disclosed

None

$60,000 of DANAHER CORPORATION lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"Education campaign with policymakers related to life sciences and biotechnology issues. Tax and tariff proposals under review and consideration by Congress and Executive Branch."

You can find more data on corporate lobbying on Quiver Quantitative.

DHR Congressional Stock Trading

Members of Congress have traded $DHR stock 8 times in the past 6 months. Of those trades, 3 have been purchases and 5 have been sales.

Here’s a breakdown of recent trading of $DHR stock by members of Congress over the last 6 months:

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

DHR Insider Trading Activity

DHR Insider Trades

DHR insiders have traded $DHR stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.

Here’s a breakdown of recent trading of $DHR stock by insiders over the last 6 months:

  • STEVEN M RALES (Chairman) has made 0 purchases and 8 sales selling 1,250,000 shares for an estimated $245,919,390.
  • CHRISTOPHER PAUL RILEY (Executive Vice President) has made 0 purchases and 2 sales selling 15,805 shares for an estimated $3,129,424.
  • TERI LIST sold 2,778 shares for an estimated $586,319

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

DHR Hedge Fund Activity

We have seen 949 institutional investors add shares of DHR stock to their portfolio, and 1,058 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

DHR Analyst Ratings

Wall Street analysts have issued reports on $DHR in the last several months. We have seen 11 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

  • Evercore ISI Group issued a "Outperform" rating on 10/07/2025
  • B of A Securities issued a "Buy" rating on 09/22/2025
  • UBS issued a "Buy" rating on 07/23/2025
  • Baird issued a "Outperform" rating on 07/23/2025
  • Guggenheim issued a "Buy" rating on 07/23/2025
  • Scotiabank issued a "Sector Outperform" rating on 07/11/2025
  • Barclays issued a "Overweight" rating on 06/24/2025

To track analyst ratings and price targets for DHR, check out Quiver Quantitative's $DHR forecast page.

DHR Price Targets

Multiple analysts have issued price targets for $DHR recently. We have seen 13 analysts offer price targets for $DHR in the last 6 months, with a median target of $230.0.

Here are some recent targets:

  • Ed Ridley-Day from Rothschild & Co set a target price of $220.0 on 10/08/2025
  • Vijay Kumar from Evercore ISI Group set a target price of $245.0 on 10/07/2025
  • Derik De Bruin from B of A Securities set a target price of $220.0 on 09/22/2025
  • Brandon Couillard from Wells Fargo set a target price of $205.0 on 07/23/2025
  • Catherine Schulte from Baird set a target price of $229.0 on 07/23/2025
  • Subbu Nambi from Guggenheim set a target price of $250.0 on 07/23/2025
  • Dan Leonard from UBS set a target price of $225.0 on 07/23/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles